Premium
Unlicensed and off‐label drug use in an I rish neonatal intensive care unit: a prospective cohort study
Author(s) -
Kieran Emily A,
O'Callaghan Noreen,
O'Donnell Colm PF
Publication year - 2014
Publication title -
acta paediatrica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.772
H-Index - 115
eISSN - 1651-2227
pISSN - 0803-5253
DOI - 10.1111/apa.12541
Subject(s) - medicine , off label use , neonatal intensive care unit , drug , prospective cohort study , pediatrics , emergency medicine , intensive care unit , cohort , intensive care medicine , pharmacology
Aim Many drugs are not licensed for use in children and drugs that are licensed may be given to them in an unapproved manner. We wanted to determine the extent of unlicensed and off‐label prescribing in our neonatal intensive care unit ( NICU ). Methods All infants admitted to our tertiary‐level NICU over 2 months were prospectively studied. We recorded demographic data, and all the drugs prescribed and compared the use of each drug to the licensed indications in the S ummary of P roduct C haracteristics. Results All the 110 infants admitted received a prescribed drug, with 69 different drugs prescribed, a median ( IQR ) of four (range: 3–11) drugs each. Just less than a fifth (19%) were unlicensed and 39% were off‐label, with 45 infants (44%) receiving both an unlicensed and off‐label drug, three (3%) receiving an unlicensed drug and 35 (32%) receiving just an off‐label drug. Most infants <32 weeks received unlicensed (91%) and off‐label (94%) drugs, and all infants <28 weeks received an unlicensed and an off‐label drug. Conclusion Most drugs prescribed to newborns are unlicensed or used for off‐label reasons. Many infants, and the majority of preterm infants, admitted to our NICU received unlicensed and off‐label drugs.